GlassScriptPhysician profile
Anthony J Mancini
NPI 1639147002
$187,484.98
in general payments reported to CMS, 2019-2025
22 companies · $610 in 2025
The $610 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,600 · 2020: $20K · 2021: $13K · 2022: $39K · 2023: $42K · 2024: $66K · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Honoraria: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Grant: $5,000 · Food and Beverage: $2,437 · Travel and Lodging: $467 · Gift: $62.20 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,568.15 |
| Honoraria | $32,868.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,900.00 |
| Grant | $5,000.00 |
| Food and Beverage | $2,437.24 |
| Travel and Lodging | $467.48 |
| Gift | $62.20 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Parapro, LLC | $73,498.23 | 2020-2024 | Natroba |
| Verrica Pharmaceuticals INC. | $41,089.82 | 2023-2025 | Ycanth |
| Novartis Pharmaceuticals Corporation | $18,672.95 | 2020-2023 | |
| Dermavant Sciences, INC. | $16,994.07 | 2024 | Tapinarof |
| Galderma Laboratories, L.P. | $7,834.12 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $7,647.44 | 2021-2025 | |
| Pfizer INC. | $7,570.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,152.51 | 2020-2024 | Dupixent |
| Nobelpharma America, LLC | $5,107.18 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $2,666.43 | 2023 | |
| Coloplast Corp | $327.86 | 2019-2025 | Coloplast Tfl Drive, Porges Coloplast |
| Antares Pharma, INC. | $179.70 | 2021-2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $174.51 | 2019-2025 | Hemangeol |
| Endo USA, INC. | $117.04 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $115.01 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.50 | 2019-2023 | |
| Incyte Corporation | $75.44 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $54.60 | 2024-2025 | Ebglyss, Taltz |
| Amgen INC. | $29.22 | 2024 | Otezla |
| Organon LLC | $25.12 | 2025 | Vtama |
| Axonics, INC. | $24.09 | 2020 | |
| Olympus America INC. | $22.91 | 2025 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Mancini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.